Research Finding a Possible Precursor to New Hypertension Drugs
Findings from research into the biological compounds which naturally help to regulate blood pressure could be a precursor to the development of a new kind of hypertension drugs.
University of California, San Diego scientists published a paper in the journal Bioorganic & Medicinal Chemistry, which detailed the potentially important discoveries.
The academics analysed the structure of the catestatin peptide which regulates cardiac function plays a role in the natural lowering of blood pressure.
A study published in Cardiovascular Research by Nihar R Mahapatra showed that plasma levels of the substance are depleted in hypertension patients, "indicating its role in the pathogenesis".
Researchers compared a 3D model of the peptide against a library of compounds to determine whether any were comparable, indicating similar clinical application.
Those identified were tested in the laboratory, and proved effective in lowering high blood pressure — these molecules could therefore lead the way for the creation of new drugs.
Dr Valentina Kouznetsova said: "Further refinement of our model should lead to the synthesis and development of a novel class of antihypertensive agents."
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.